Northwest Biotherapeutics Number Of Shares Shorted vs. Gross Profit
| NWBO Stock | USD 0.26 0.01 3.70% |
For Northwest Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Northwest Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Northwest Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Northwest Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Northwest Biotherapeutics over time as well as its relative position and ranking within its peers.
Northwest |
Northwest Biotherapeutics Gross Profit vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Northwest Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Northwest Biotherapeutics value to that of its competitors to determine the firm's financial worth. Northwest Biotherapeutics is considered to be number one stock in number of shares shorted category among its peers. It also is considered to be number one stock in gross profit category among its peers fabricating about 0.07 of Gross Profit per Number Of Shares Shorted. The ratio of Number Of Shares Shorted to Gross Profit for Northwest Biotherapeutics is roughly 14.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Northwest Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Northwest Biotherapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Northwest Gross Profit vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Northwest Biotherapeutics |
| = | 14.14 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Northwest Biotherapeutics |
| = | 1 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Northwest Gross Profit Comparison
Northwest Biotherapeutics is currently under evaluation in gross profit category among its peers.
Northwest Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Northwest Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Northwest Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Northwest Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Northwest Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
Northwest Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Northwest Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Northwest Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Northwest Biotherapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Northwest Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Use Investing Themes to Complement your Northwest Biotherapeutics position
In addition to having Northwest Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Northwest OTC Stock
To fully project Northwest Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Northwest Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Northwest Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.